Argenx

News

argenx's Forte acquisition delivers coeliac trial win

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

News

Argenx pens $2.2bn deal to buy autoimmune biotech Forte

Netherlands- and Belgium-based argenx has agreed to buy US biotech Forte Bio for up to $2.2bn, bolstering its autoimmune disease pipeline.

News

Argenx poised to expand Vyvgart market off new phase 3 data

New data could expand the label of argenx's Vyvgart to include AChR-Ab seronegative patients, ~20% of gMG patients whose current options are limited.

News

J&J's 'Swiss army knife' drug gets first FDA approval

Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for generalised myasthenia gravis (gMG).

News

J&J launches gMG market bid with nipocalimab filing

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete wit

News

FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug t

argenx's Forte acquisition delivers coeliac trial win

Argenx pens $2.2bn deal to buy autoimmune biotech Forte

Argenx poised to expand Vyvgart market off new phase 3 data

J&J's 'Swiss army knife' drug gets first FDA approval

J&J launches gMG market bid with nipocalimab filing

FDA clears Argenx’ Vyvgart Hytrulo for rare disease CIDP

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

Argenx

Editor's Picks